Literature DB >> 24253442

FOP: still turning into stone.

Reza Taslimi1, Saba Jafarpour, Nahid Hassanpour.   

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare catastrophic genetic condition of extraskeletal (heterotopic) ossification. One in every two million people is affected worldwide, with no ethnic, racial, gender, or geographic predisposition. Most cases of FOP arise from a spontaneous missense mutation in the gene encoding bone morphogenic protein (BMP) type II receptor (ACVR1/ALK2). Affected individuals are normal at birth apart from malformed great toes. Onset of clinical symptoms is usually in the first decade of life, presenting with episodic emergence of painful rapidly appearing tumor-like soft tissue swellings (flare-ups). Heterotopic bone replaces the skeletal muscles, tendons, ligaments, and connective tissue at the site of the damage through a process of endochondral ossification, causing fixation of joints and permanent limitation of motion. Most affected individuals are confined to wheelchair in the third decade of life. Worldwide rate of misdiagnosis of FOP is very high; clinicians often fail to associate the two classic clinical features of FOP: rapidly developing soft tissue swellings and the abnormal great toes. The current case presents a previously undiagnosed 39-year-old FOP patient, sadly a victim of lack of clinical awareness of this rare condition. As a result of repetitive iatrogenic harm, he has tragically "turned into stone."

Entities:  

Mesh:

Year:  2013        PMID: 24253442     DOI: 10.1007/s10067-013-2417-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  22 in total

1.  Are great toes always abnormal in patients with fibrodysplasia ossificans progressiva?

Authors:  Sumeet Gulshan Dua; Nilendu C Purandare
Journal:  Eur J Pediatr       Date:  2011-02-02       Impact factor: 3.183

2.  Fibrodysplasia (myositis) ossificans progressiva. Clinical lessons from a rare disease.

Authors:  R Smith
Journal:  Clin Orthop Relat Res       Date:  1998-01       Impact factor: 4.176

3.  The hand and foot malformations in fibrodysplasia ossificans progressiva.

Authors:  H W Schroeder; M Zasloff
Journal:  Johns Hopkins Med J       Date:  1980-08

4.  Fibrodysplasia ossificans progressiva. A survey of forty-two cases.

Authors:  J G Rogers; W B Geho
Journal:  J Bone Joint Surg Am       Date:  1979-09       Impact factor: 5.284

5.  Evaluation of 20 years experience of fibrodysplasia ossificans progressiva in Iran: lessons for early diagnosis and prevention.

Authors:  Seyed Reza Raees-Karami; Hanieh Jafarieh; Vahid Ziyayi; Reza Shekarriz Foumani; Yahya Aghighi
Journal:  Clin Rheumatol       Date:  2012-04-20       Impact factor: 2.980

6.  Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients.

Authors:  J M Connor; D A Evans
Journal:  J Bone Joint Surg Br       Date:  1982

7.  When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP).

Authors:  Frederick S Kaplan; Jay Groppe; Eileen M Shore
Journal:  Drug Discov Today Ther Strateg       Date:  2008

Review 8.  Fibrodysplasia (myositis) ossificans progressiva.

Authors:  A J Bridges; K C Hsu; A Singh; R Churchill; J Miles
Journal:  Semin Arthritis Rheum       Date:  1994-12       Impact factor: 5.532

Review 9.  Fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Martine Le Merrer; David L Glaser; Robert J Pignolo; Robert E Goldsby; Joseph A Kitterman; Jay Groppe; Eileen M Shore
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-03       Impact factor: 4.098

10.  Fibrodysplasia ossificans progressiva: report of a case and review of articles.

Authors:  J Hashemi; A Shahfarhat; A Beheshtian
Journal:  Iran J Radiol       Date:  2011-09-25       Impact factor: 0.212

View more
  1 in total

1.  Evaluation of Salivary Cytokines for Diagnosis of both Trauma-Induced and Genetic Heterotopic Ossification.

Authors:  Hsiao Hsin Sung Hsieh; Michael T Chung; Ronald M Allen; Kavitha Ranganathan; Joe Habbouche; David Cholok; Jonathan Butts; Arminder Kaura; Ramkumar Tiruvannamalai-Annamalai; Chris Breuler; Caitlin Priest; Shawn J Loder; John Li; Shuli Li; Jan Stegemann; Steven L Kunkel; Benjamin Levi
Journal:  Front Endocrinol (Lausanne)       Date:  2017-04-24       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.